Navigation Links
Danaher Reports Record Second Quarter 2013 Results

WASHINGTON, July 18, 2013 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) today announced results for the second quarter of 2013.  All financial metrics in this release reflect only the Company's continuing operations unless otherwise noted.

Net earnings for the quarter ended June 28, 2013 were $616.8 million, or $0.87 per share on a diluted basis, a 3.5% increase over diluted net earnings per share of $0.84 for the second quarter of 2012.  As summarized in the attached reconciliation schedule, included in the second quarter 2012 diluted net earnings per share is a $0.03 benefit from discrete tax items, a lower than anticipated income tax rate, as well as a gain from resolving a contingency related to a prior asset disposal.  Excluding these gains, adjusted diluted net earnings per share increased 7.5% from the second quarter of 2012 to the second quarter of 2013.

Revenues for the quarter were $4.7 billion, 4% higher than the $4.6 billion reported for the second quarter of 2012.  Core revenues increased 2.5% in the second quarter of 2013 compared to the second quarter of 2012.

The Company anticipates that GAAP diluted net earnings per share for the quarter ending September 27, 2013 will be in the range of $0.78 to $0.83.  The Company narrowed its full year 2013 adjusted diluted net earnings per share guidance to $3.37 to $3.42 from a previous range of $3.32 to $3.47.

H. Lawrence Culp, Jr., President and Chief Executive Officer, stated, "Core revenue growth in the quarter was slightly better than we anticipated and, combined with our team's outstanding execution, led to earnings outperformance, excellent margin expansion and superior cash flow.  As we look to the second half of the year, we maintain a conservative macro outlook, while remaining confident in our ability to deliver solid operating margin expansion.  Our earnings outperformance in the second quarter allows us to make additional high impact growth investments and to fund productivity and efficiency initiatives that we believe will position us well for the balance of 2013 and beyond."

Danaher will discuss its results during its investor conference call today starting at 8:00 a.m. EDT.  The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website at  A replay of the webcast can be accessed on the "Investors" section of Danaher's website, under the subheading "Investor Events," shortly after the conclusion of the presentation, and will remain available until the next quarterly earnings call.  The conference call can be accessed by dialing 888-726-2470 within the U.S. or by dialing 913-312-1475 outside the U.S. a few minutes before the 8:00 a.m. EDT start and telling the operator that you are dialing in for Danaher's earnings conference call (access code 5527091).  A replay of the conference call will be available shortly after the conclusion of the call and through Thursday, July 25, 2013.  The replay can be accessed by dialing 888-203-1112 within the U.S. or 719-457-0820 outside the U.S. with the access code 5527091.  In addition, presentation materials relating to Danaher's results have been posted to the "Investors" section of Danaher's website under the subheading "Financial Information – Quarterly Earnings."

Danaher is a science and technology leader that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers.  Our premier brands are among the most highly recognized in each of the markets we serve.  The Danaher Business System provides a foundation to our 63,000 associates around the world, serving customers in more than 125 countries.  In 2012, we generated $18.3 billion of revenue.  For more information please visit our website:

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), this earnings release also contains non-GAAP financial measures. The reasons why we believe these measures provide useful information to investors, a reconciliation of these measures to the most directly comparable GAAP measures and other information relating to these measures are included in the supplemental reconciliation schedule attached.

Statements in this release that are not strictly historical, including the statements regarding the Company's anticipated diluted net earnings per share for the third quarter and full year 2013, the macro-economic outlook, the Company's ability to expand operating margins, the Company's investments in growth and in productivity and efficiency initiatives and the potential impact thereof, the Company's positioning for the balance and 2013 and beyond and any other statements regarding events or developments that we believe or anticipate will or may occur in the future, are "forward-looking" statements within the meaning of the federal securities laws.  There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things, deterioration of or instability in the economy and financial markets, the impact of our restructuring activities on our ability to grow, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our ability to successfully identify, consummate and integrate appropriate acquisitions, contingent liabilities relating to acquisitions and divestures, our compliance with applicable laws and regulations (including regulations relating to medical devices and the healthcare industry) and changes in applicable laws and regulations, our ability to effectively address cost reduction and other changes in the healthcare industry, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, risks relating to product defects and recalls, risks relating to product manufacturing, the impact of our debt obligations on our operations, our relationships with and the performance of our channel partners, commodity costs and surcharges, our ability to adjust purchases and  manufacturing capacity to reflect market conditions, labor matters,  international economic, political, legal and business factors, disruptions relating to man-made and natural disasters, security breaches or other disruptions of our information technology systems and pension plan costs.  Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2012 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the second quarter of 2013. These forward-looking statements speak only as of the date of this release and the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.


DANAHER CORPORATIONCONSOLIDATED CONDENSED STATEMENTS OF EARNINGS($ and shares in millions, except per share amounts)(unaudited) Three Months EndedSix Months EndedJune 28, 2013June 29, 2012June 28, 2013June 29, 2012Sales





8,869.7Cost of sales

(2,242.0)(2,198.0)(4,361.0)(4,278.7)Gross profit

2,495.52,355.54,821.24,591.0Operating costs and other:Selling, general and administrative expenses

(1,339.7)(1,278.6)(2,638.1)(2,523.5)Research and development expenses

(312.2)(283.6)(608.6)(553.7)Earnings from unconsolidated joint venture

—18.0—32.4Operating profit

843.6811.31,574.51,546.2Non-operating income (expense):Gain on sale of unconsolidated joint venture

——229.8—Interest expense

(39.4)(37.9)(78.6)(77.3)Interest income from continuing operations before income taxes

805.8774.11,728.21,470.3Income taxes

(189.0)(173.9)(419.5)(350.1)Net earnings from continuing operations

616.8600.21,308.71,120.2Earnings from discontinued operations, net of income taxes

———92.9Net earnings





1,213.1Net earnings per share from continuing operations:Basic










1.57Net earnings per share from discontinued operations:Basic










0.13Net earnings per share:Basic










1.70Average common stock and common equivalent shares outstanding:Basic


709.8714.9709.1714.5This information is presented for reference only. A complete copy of Danaher's Form 10-Q financial statements is available on the Company's website ( CORPORATIONRECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES($ in millions except per share data) 

Second Quarter Earnings Per ShareThree Months Ended%June 28, 2013June 29, 2012IncreaseDiluted Net Earnings Per Share from Continuing Operations$0.87$0.843.5%Gains from discrete tax items and reduction of anticipated

 effective tax rate ($11 million)—(0.02)2012 gain on resolution of contingencies associated with

previously disposed assets ($11 million pre-tax, $8 million


—(0.01)Adjusted Diluted Net Earnings Per Share from Continuing Operations (Non-GAAP)$0.87$0.817.5%Forecasted Earnings Per Share Three Months EndingYear EndingSeptember 27, 2013December 31, 2013Low EndHigh EndLow EndHigh EndDiluted Net Earnings Per Share from Continuing Operations$0.78$0.83$3.60$3.65Gain on the sale of investment in Apex Tool 

Group LLC in the first quarter of 2013 ($230

million pre-tax, $144 million after-tax)

——(0.20)(0.20)Gain from retroactive reinstatement of

certain federal tax provisions contained in the

American Tax Relief Act of 2012 and other

discrete tax items.

——(0.03)(0.03)Adjusted Diluted Net Earnings Per Share from Continuing Operations (Non-GAAP)$0.78$0.83$3.37$3.42 

 Core Revenue GrowthComponents of Revenue GrowthThree Months Ended June 28, 2013 vs. Comparable 2012 PeriodCore (Non-GAAP)


%Acquisitions (Non-GAAP)


%Impact of Currency Translation (Non-GAAP)


%Total Revenue Growth (GAAP)


Adjusted Diluted Net Earnings Per Share from Continuing Operations We disclose the non-GAAP measure of adjusted diluted net earnings per share from continuing operations, which refers to GAAP diluted net earnings per share from continuing operations, excluding the items identified in the reconciliation schedule above.  This non-GAAP measure should be considered in addition to, and not as a replacement for or superior to, the comparable GAAP measure, and may not be comparable to similarly titled measures reported by other companies.

Management believes that this measure provides useful information to investors by reflecting additional ways of viewing Danaher's operations that, when reconciled to the corresponding GAAP measure, helps our investors to better understand the long-term profitability trends of our business, and facilitates easier comparisons of our profitability to prior and future periods and to our peers.  The items described above have been excluded from this non-GAAP measure because items of this nature and/or size occur with inconsistent frequency, occur for reasons that may be unrelated to Danaher's commercial performance during the period and/or we believe are not indicative of Danaher's ongoing operating costs or gains in a given period, which we believe may obscure underlying business trends and make comparisons of long-term performance difficult.  The Company deems acquisition-related transaction costs incurred in a given period to be significant (generally relating to the Company's larger acquisitions) if it determines that such costs exceed the range of acquisition-related transaction costs typical for Danaher in a given period.

The Company estimates the tax effect of the items identified in the reconciliation schedule above by applying the Company's overall estimated effective tax rate to the pre-tax amount, unless the nature of the item and/or the tax jurisdiction in which the item has been recorded requires application of a specific tax rate or tax treatment, in which case the tax effect of such item is estimated by applying such specific tax rate or tax treatment.

Core Revenue and Core Revenue GrowthWe use the term "core revenue" or "sales from existing businesses" to refer to GAAP revenue from existing operations excluding (1) sales from acquired businesses recorded prior to the first anniversary of the acquisition less the impact from the divestiture of a product line the sales of which (prior to the divestiture) were included in sales from acquired businesses ("acquisition sales"), and (2) the impact of currency translation.  The portion of GAAP revenue  from existing operations attributable to currency translation is calculated as the difference between (a) the period-to-period change in revenue (excluding acquisition sales) and (b) the period-to-period change in revenue (excluding acquisition sales) after applying current period foreign exchange rates to the prior year period.  We use the term "core revenue growth" to refer to the measure of comparing current period core revenue with the corresponding period of the prior year.  These non-GAAP measures should be considered in addition to, and not as a replacement for or superior to, the comparable GAAP measures, and may not be comparable to similarly titled measures reported by other companies.

Management believes that this measure provides useful information to investors by helping identify underlying growth trends in our business and facilitating easier comparisons of our revenue performance with prior and future periods and to our peers.  We exclude the effect of currency translation from these measures because currency translation is not under management's control, is subject to volatility and can obscure underlying business trends. We exclude the effect of acquisitions because the nature, size and number of acquisitions can vary dramatically from period to period and between us and our peers, which we believe may obscure underlying business trends and make comparisons of long-term performance difficult. 

SOURCE Danaher Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Danaher Reports Record First Quarter 2013 Results
2. Danaher Reports Record Fourth Quarter 2012 Results
3. Pharmsynthez Reports Full Year 2012 Results in line US GAAP Financial Reporting
4. Johnson & Johnson Reports 2013 Second-Quarter Results:
5. South Asia Medical Device Market Reports
6. Russia & the CIS Medical Device Market Reports
7. Respiratory Motion, Inc. Reports Important New Data On The ExSpiron Respiratory Monitor, The First Monitor To Provide Continuous Minute Ventilation Data In Non-Ventilated Patients
8. Membrane Microfiltration Market and Membrane Separation Technologies Research Reports
9. Avanir Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
10. Isis Reports Phase 2 Data on ISIS-APOCIII Rx Showing Significant Reductions in Triglycerides and APOC-III in Patients with High Triglycerides and Type 2 Diabetes
11. Elcelyx Therapeutics Reports Positive Data for NewMet in Type 2 Diabetes at 2013 American Diabetes Association Scientific Sessions
Post Your Comments:
(Date:10/9/2015)... , Oct. 9, 2015 Henry ... largest provider of health care products and services to ... its customers that the Henry Schein Disaster Relief Hotline ... operational, logistical or financial issues as a result of ... . The toll-free number for all Henry Schein ...
(Date:10/9/2015)... 9, 2015  Impax Laboratories, Inc. (NASDAQ: IPXL ... third quarter 2015 financial results on Monday, November 9, ... markets. The Company will host a conference call and ... Eastern Time on November 9, 2015.  ... The financial results and live webcast will be ...
(Date:10/9/2015)... Eli Lilly and Company (NYSE: LLY ) today announced ... jobs to its research and development presence at the Alexandria ... . --> --> ... translational immuno-oncology hub and a Lilly "portal," which will provide ... drug discovery capabilities, including chemistry and lead optimization expertise. ...
Breaking Medicine Technology:
... Society for Cardiovascular Angiography and Interventions (SCAI) 2011 Scientific ... measure and improve quality in the cath lab for ... of using evidence to guide new ways to advance ... quality program with its signature "Quality Improvement Toolkit" to ...
... Bank Pharmaceuticals today announced it has been awarded an ... Institute of Allergy and Infectious Diseases for the development ... treatment of Hepatitis B virus infection.   Under ... $3.9 million over five years in support of its development ...
Cached Medicine Technology:
(Date:10/9/2015)... ... 09, 2015 , ... The American Osteopathic Foundation (AOF) has ... Education J. Michael Finley, DO, as the recipient of the 2015 W. Douglas ... on graduate medical education opportunities for osteopathic residents, and his dedication to promoting ...
(Date:10/9/2015)... (PRWEB) , ... October 09, 2015 , ... "My spouse ... our canes falling when leaned against something," said an inventor from Buffalo, N.Y. "This ... cane users face daily." , The CANE REST enables a user to keep a ...
(Date:10/9/2015)... ... October 09, 2015 , ... Matrix IT Medical ... specifications for TRACTUS, the world’s first sterile field scanner. , The ... to the FDA’s recent Unique Device Identifier (UDI) Final Rule, which will require ...
(Date:10/9/2015)... , ... October 09, 2015 , ... "As a nurse, ... inventors from Philadelphia, Pa. "They have to wear large diapers or pads. We came ... They developed the TROUSAFE to absorb urine leaking from the tip of the penis. ...
(Date:10/9/2015)... ... October 09, 2015 , ... Ryan Fox, ... largest recreational dispensaries in Colorado, says the latest figures on the state’s sales ... maturing into a legitimate industry. , Last month, according to the ...
Breaking Medicine News(10 mins):
... University researcher will receive a $2.3 million New Innovator ... of synthetic platelets and the technology that makes them ... uses nanotechnology to build platelets of biodegradable polymers, which ... She and fellow researchers initially pursued the technology ...
... (Boston) - Boston Medical Center (BMC) has been awarded ... Heart, Lung and Blood Institute (NHLBI) for investigators from ... Center for Health Insurance Reform, Cardiovascular Outcomes and Disparities. ... understand the effects of Massachusetts health reform on cardiovascular ...
... Reporter , WEDNESDAY, Sept. 29 (HealthDay News) -- Another study ... screening can lower the risk of dying from breast cancer ... Sweden, found that women who were screened cut their risk ... over a 10-year period would save one life, study author ...
... by principal investigator Kang Zhang, MD, PhD, professor of ... Eye Center and director of UCSD,s Institute of Genomic ... NIH Transformative Award. Zhang and co-principal investigators Sheng ... Reh, PhD from the University of Washington, received the ...
... of immunotherapy to children with neuroblastoma, a nervous system ... and free of disease progression after two years, according ... School of Medicine and fellow institutions. The percentage rose ... to 66 percent for children receiving immunotherapy plus standard ...
... - Patients with triple negative breast cancer that also have ... risk of recurrence, compared to those with the same disease ... University of Texas MD Anderson Cancer Center. The findings ... this select group of triple negative breast cancer patients, as ...
Cached Medicine News:
... general purpose incubators designed to ... and uniformity required for the ... versatile microprocessor controlled incubators feature ... easy-to-read digital display, and built-in ...
... Economy Incubators available in five different models. ... 1.4 cu. Ft. (39 liters), 2.5 cu. ... (129 liters. Equally important, Precision Economy Incubators ... temperature sensitivity, stability, and uniformity. As a ...
... five different models. Choose mechanical or gravity ... liters), 2.5 cu. Ft. (71.5 liters), or ... Precision Economy Incubators combine a wide temperature ... uniformity. As a result, you will find ...
Binocular indirect ophthalmic lenses. Small pupil diagnosis & treatment....
Medicine Products: